Synthesis of 18F-PSMA-1007 by one-step method and PET/CT imaging in prostate cancer
10.3760/cma.j.issn.2095-2848.2019.10.007
- VernacularTitle: 一步法合成18F-PSMA-1007及其对前列腺癌的PET/CT显像
- Author:
Xing ZHOU
1
,
2
;
Taipeng SHEN
3
;
Yutang YAO
3
;
Hao LU
3
;
Shirong CHEN
3
;
Dingqiong XIAO
3
;
Meng ZHAO
3
;
Guohui XU
3
;
Jinhui YOU
1
;
Zhuzhong CHENG
1
,
2
Author Information
1. School of Medical Imaging, North Sichuan Medical College, Nanchong 637000, China
2. Radiation Oncology Key Laboratory of Sichuan Province, PET/CT Centre, Sichuan Cancer Hospital & Institute, Chengdu 610041, China
3. Radiation Oncology Key Laboratory of Sichuan Province, PET/CT Centre, Sichuan Cancer Hospital & Institute, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
Prostate neoplasms;
Prostate-specific membrane antigen;
Fluorine radioisotopes;
Chemical synthesis;
Positron-emission tomography
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(10):606-609
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To synthesize and analyze 18F-prostate specific membrane antigen (PSMA)-1007, followed by its imaging in prostate cancer.
Methods:Based on one-step method, 18F-PSMA-1007 was produced by the CFN-MPS-200 automatic synthesis module and its quality analysis was conducted. 18F-PSMA-1007 PET/CT imaging was performed in a prostate cancer patient (66 years old).
Results:The synthesis time of 18F-PSMA-1007 was about 50 min, and the radiochemical yield was (25.0±5.0) % (attenuation correction, n=3). The radiochemical purity was above 99.0% and was above 98.0% after 6 h. The product was colorless transparent solution with pH value of 7.0-7.5, and the specific activity was (410.0±11.0) MBq/ml and the radioactive nuclear purity was above 99.0%. PET/CT imaging in the patient showed that 18F-PSMA-1007 was highly concentrated in prostate cancer with maximum standardized uptake value (SUVmax) of 40.9.
Conclusion:Based on CFN-MPS-200 multifunction synthesis module, 18F-PSMA-1007 can be stably synthesized with high radiochemical yield and can be concentrated in prostate cancer.
